Abstracts tagged "B-Cell Targets"

Abstract Number: 1956 • ACR Convergence 2023
Rituximab Treatment in Adult Patients with Idiopathic Inflammatory Myositis (IIM): A Systematic Review and Meta-analysis
Lilian Otalora Rojas¹, Karishma Ramsubeik², Luis Sanchez-Ramos², Shastri Motilal³, Jasvinder Singh⁴ and Gurjit S Kaeley⁵, ¹University of Florida, Ponte Vedra Beach, FL, ²University of Florida, Jacksonville, FL, ³The University of the West Indies, St. Augustine, Trinidad and Tobago, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Florida College of Medicine – Jacksonville, Ponte Vedra Beach, FL
Background/Purpose: Autoimmune myositis involves a spectrum of rare autoimmune disorders characterized by inflammation and damage to skeletal muscles. The management of these challenging conditions often…
Abstract Number: 0222 • ACR Convergence 2023
Predictors of Adverse Prognosis Following Hospitalization for COVID-19 Infection in Patients with Immune Mediated Inflammatory Diseases Treated with Rituximab
Pei-hsinq Lai¹, Ting-wei Chang², Shih-hsun Lan², Chiao-Feng Cheng², Cheng-Hsun Lu² and Song-Chou Hsieh², ¹Taipei City Hospital, Zhongxiao Branch, Taipei, Taiwan, ²National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Rituximab (RTX) is widely used in immune mediated inflammatory disease (IMID) patients refractory to conventional treatment. Previous studies have indicated that RTX in IMID…
Abstract Number: 0926 • ACR Convergence 2023
Single-cell Multi-Omic Evaluation of Differences in Immune Cell Populations in Progression Toward Systemic Lupus Erythematosus
Aleksandra Bylinska, Miles Smith, Samantha Slight-Webb, Carla Guthridge, Caleb Marlin, Kevin Thomas, Christian Wright, Marci Beel, Susan Macwana, Wade DeJager, Judith James and Joel Guthridge, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Several groups of individuals are at higher risk for SLE, including those with African American ancestry (AA), lupus-associated autoantibodies (ANA+), or some clinical symptoms…
Abstract Number: 2191 • ACR Convergence 2023
Efficacy of anti-CD38 Treatment with Daratumumab in Two Cases of Refractory and Severe Sjogren Disease
Gaetane Nocturne¹, Mathilde di Filippo², Oriane Marmontel², Pascale Chretien¹, Roman Krzysiek¹, François Lifermann³, Nawal Rahal¹, Rakiba Belkhir⁴, Philippe Moulin² and Xavier Mariette⁵, ¹APHP, Le Kremlin-Bicêtre, France, ²Hospices Civils de Lyon, Lyon, France, ³Department of Internal Medicine, Centre Hospitalier de Dax, Dax, France, ⁴Rheumatology Department, Université Paris-Saclay, INSERM U1184, Hôpital Bicêtre, APHP, FHU CARE, Le Kremlin-Bicêtre, France, ⁵Université Paris-Saclay, Le Kremlin-Bicêtre, France
Background/Purpose: Sjögren's disease (Sjo) is a systemic autoimmune disease. In 80% of the patients, Sjo is responsible for dryness, fatigue, and joint pain. In 10%…
Abstract Number: 0425 • ACR Convergence 2023
Long-term Safety of Rituximab in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Ioasaf Karafotias, Joshua Rothwell, Maryam Adas, Bechman Katie, Mark Russell, Sam Norton and James Galloway, King's College London, London, United Kingdom
Background/Purpose: Rituximab targets CD20-bearing B cells and is used to treat Rheumatoid Arthritis (RA). Common Variable Immune Deficiency (CVID) is a primary immune deficiency syndrome…
Abstract Number: 0956 • ACR Convergence 2023
Effects of B Cell Depletion by CD19-targeted CAR-T Cells in a Murine Model of Systemic Sclerosis
Jérôme Avouac¹, Anne Cauvet², Cindy Orvain³, Morgane boulch⁴, Philippe Bousso⁴ and Yannick ALLANORE⁵, ¹Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre – Université Paris Cité, Paris, France, ²INSERM U1016, Paris, France, ³INSERM U1016, Paris, ⁴Institut Pasteur, Paris, France, ⁵Université Paris Cité, Paris, France
Background/Purpose: Chimeric antigen receptor (CAR)-T cells represent a potentially curative strategy for B cell malignancies. A first successful clinical experience has been recently reported in…
Abstract Number: 2310 • ACR Convergence 2023
Machine Learning Approaches for Prediction of Renal Flares in Systemic Lupus Erythematosus: Knowledge-Driven Models Outperformed Data-Driven Models
Nursen Cetrez¹, Julius Lindblom¹, Raffaele Da Mutten², Dionysis Nikolopoulos² and Ioannis Parodis¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden
Background/Purpose: Renal flares in patients with SLE result in significant nephron loss. Thus, identification of reliable early signals of impending renal flares is anticipated to…
Abstract Number: 0550 • ACR Convergence 2023
Harnessing Machine Learning to Predict Neuropsychiatric Events in Systemic Lupus Erythematosus
Nursen Cetrez¹, Julius Lindblom¹, Raffaele Da Mutten², Dionysis Nikolopoulos² and Ioannis Parodis¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) is linked to increased morbidity, mortality, and adverse health-related quality of life. Early disease, a history of NPSLE, aPL…
Abstract Number: 0983 • ACR Convergence 2023
Association Between Disease-modifying Anti-rheumatic Drugs and Short-term Outcomes of Dengue: A Population-based, Cohort Study
I-Feng Lin¹, Hsin-Hua Chen², Theodore Tsai³ and Nicole Huang⁴, ¹National Yang Ming Chiao Tung University, Taipei, Taiwan, ²Taichung Veterans General Hospital, Taichung, Taiwan, ³Takeda Vaccines, Cambridge, MA, ⁴Master of Public Health Program, National Yang Ming Chiao Tung University, Taipei, Taiwan
Background/Purpose: Dengue is the leading vectorborne disease globally with half of the global population at risk, including Puerto Rico in the United States. Previously, we…
Abstract Number: 2320 • ACR Convergence 2023
Predicting Remission and Low Disease Activity Attainment in Patients with Systemic Lupus Erythematosus
Raffaele Da Mutten¹, Nursen Cetrez², Julius Lindblom², Shereen Oon³, Dionysis Nikolopoulos¹, Mandana Nikpour⁴ and Ioannis Parodis², ¹Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³St Vincent's Hospital, Fitzroy, Australia, ⁴The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia
Background/Purpose: Response to therapy in SLE varies significantly and presents a considerable challenge in terms of predictability. Development of predictive models with ability to accurately…
Abstract Number: 0583 • ACR Convergence 2023
Therapeutic Potential of Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, for the Treatment of Refractory Autoimmune Disease Patients
Racquel Domingo-Gonzalez¹, Isabelle Baribaud², Miho Oyasu¹, Sivani Pandey¹, Maya Leabman¹, Genevive Hernandez¹, Albert Candia¹, Stephen Carroll¹, Bruce Keyt¹, Maya Kotturi¹, Carrie Brodmerkel² and Mary Beth Harler², ¹IGM Biosciences, Inc., Mountain View, CA, ²IGM Biosciences, Inc., Doylestown, PA
Background/Purpose: B cell depletion therapy (BCDT) with conventional IgG antibodies (e.g.rituximab) has been used to treat autoimmune (AI) disease for several decades. However, many patients…
Abstract Number: 1076 • ACR Convergence 2023
Rituximab-Associated Hypogammaglobulinemia in Patients with Rheumatic Diseases: A Multicenter Retrospective Observational Study
Olga Rusinovich¹, Enrique Calvo-Aranda², Claudia Maria Gomez², Patricio Cardoso Peñafiel², Pilar Navarro Alonso³, Miguel Cantalejo Moreira⁴, Alberto Diaz y Oca³, Pablo Navarro⁵, Maria Machattou⁵, Maria Alonso⁵, Carlota Navarro⁵, Carolina Merino⁵, Hilda Godoy⁶, Maria Carmen Barbadillo Mateos⁷, Carlos Isasi⁵, Maria Perez Ferro⁸, Jessica Polo⁹, Veronica Garcia¹⁰, Jose Luis Andreu-Sánchez¹¹, Jose Campos¹² and Jesus Sanz¹³, ¹Puerta de Hierro Majadahonda University Hospital, Boadilla del Monte, Spain, ²Hospital Universitario Infanta Leonor, Madrid, Spain, ³Fuenlabrada University Hospital, Madrid, Spain, ⁴Hospital Universitario de Fuenlabrada, Madrid, Spain, ⁵Puerta de Hierro Majadahonda University Hospital, Madrid, Spain, ⁶Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁷Public, Madrid, Spain, ⁸Hospital Universitario Rey Juan Carlos, Madrid, Spain, ⁹Rey Juan Carlos University Hospital, Madrid, Spain, ¹⁰Ramon y Cajal University Hospital, Madrid, Spain, ¹¹Rheumatology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ¹²Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain, ¹³Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: Rituximab (RTX) is a murine/human chimeric monoclonal antibody directed against the CD20 receptor expressed on pre-B and mature B cells. Rituximab is used effectively…
Abstract Number: 2342 • ACR Convergence 2023
Modulation of B Cell and Interferon Pathways by Ianalumab in Patients with Systemic Lupus Erythematosus: Findings from a Phase 2 Clinical Trial
Aida Santos da Costa¹, Thomas Dörner², Andrea Grioni¹, Alexandre Avrameas¹, Ulrike Sommer¹, Rainer Hillenbrand¹, Valeria De Luca¹, Enrico Ferrero¹, Andre Nogueira da Costa¹, Isabelle Isnardi¹ and Stephen J Oliver¹, ¹Novartis Pharma AG, Basel, Switzerland, ²Department of Medicine, Rheumatology and Clinical Immunology, Charité Universitätsmedizin and Deutsches Rheumaforschungszentrum, Berlin, Germany
Background/Purpose: Ianalumab (VAY736) is an afucosylated monoclonal antibody targeting the B cell activating factor receptor (BAFFR) that depletes B cells via enhanced antibody dependent cellular…
Abstract Number: 0588 • ACR Convergence 2023
Long Term Safety and Predictors of Serious Infections Among Patients with Systemic Lupus Erythematosus Treated with Rituximab: Audit from a Single Center Biologic Registry
Augustine Jose¹, Aishwarya Gopal¹, Mamatha Gorijavolu¹, Anna C Das², Jagan Babu K L¹, Amrita Nayak¹, Chengappa Kavadichanda¹ and Molly Mary Thabah¹, ¹Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ²St.Johns National Academy of Health Sciences, Bengaluru, India
Background/Purpose: Rituximab (RTX) is increasingly being employed to treat refractory systemic lupus erythematosus(SLE). Though the drug is effective there is a high risk of adverse…
Abstract Number: 1272 • ACR Convergence 2023
Immunomodulators and Risk for Breakthrough COVID-19 After a Third SARS-CoV-2 mRNA Vaccine Among Patients with Rheumatoid Arthritis: A Cohort Study
Abigail Schiff¹, Xiaosong Wang¹, Naomi Patel², Yumeko Kawano¹, Jennifer Hanberg³, Emily Kowalski¹, Claire Cook², Kathleen Vanni¹, Grace Qian¹, Katarina Bade⁴, Alene Saavedra¹, Shruthi Srivatsan², Zachary Williams², Rathnam Venkat¹, Zachary Wallace⁵ and Jeffrey Sparks⁶, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Massachusetts General Hospital, Newton, MA, ⁶Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: In August 2021, the CDC recommended a third SARS-CoV-2 mRNA vaccine dose to complete the initial vaccine series for immunosuppressed patients who had previously…

« Previous Page
1
…
5
6
7
8
9
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].